tnf-β

1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(7-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl)urea, a TNF-α agonistic compound, could induce cells to secrete TNF- α.

TNF-α-IN-1 is a TNF-α inhibitor.

TNF-α (31-45), human, is a peptide of tumor necrosis factor-α.

TNF-α-IN-25 exhibits weak to moderate inhibition of the hERG-encoded potassium ion channel, with a hERG IC50 value of 9.2 μM.

TNF-α-IN-26 (Compound 18) is a TNF-α inhibitor, exhibiting an IC50 of 0.10 μM for the CSBP ligand. It suppresses LPS-stimulated TNF production in mouse models and is applicable in research on inflammatory diseases.

TNF-α-IN-6 is an orally efficacious, allosteric inhibitor of TNFα (K_D = 6.8 nM).

TNF-α (31-45), human (TFA), is a peptide of tumor necrosis factor-α (TNF alpha), an inflammatory cytokine that induces necrosis or apoptosis.

TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor with a dissociation constant (K D) of 12.06 μM. It impedes TNF-α-induced caspase activation and the NF-κB signaling pathway by binding to TNF-α, suppressing the phosphorylation of IκBα and the nuclear migration of NF-κB p65. This compound is utilized in the study of TNF-α-mediated autoimmune diseases [1].

TNF-α-IN-10 (compound 8a) is an inhibitor of IL-6 and TNF-α, exhibiting anti-inflammatory activity [1].

TNF-α-IN-18 (Compound 61) is a small molecule inhibitor of tumor necrosis factor-alpha (TNF-α) that operates with a IC50 of 1.8µM. TNF-α-IN-18 effectively blocks the nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), thereby suppressing the downstream TNF signaling pathway; TNF-α-IN-18 exhibits minimal cytotoxicity in mouse fibroblast LM cells with a CC50 greater than 50 µM. TNF-α-IN-18has been shown to alleviate sepsis induced by TNF or lipopolysaccharide in mouse models, and provides significant protection against the development and progression of rheumatoid arthritis in murine models.

TNF-α-IN-22 (Compound 30) is a TNFα inhibitor that induces apoptosis by inhibiting TNFα-induced IkBα downregulation and blocking the cell cycle. It is applicable for research in triple-negative breast cancer.

TNF-α-IN-24 (Example 15) is a TNF-α inhibitor with an IC50 value of 4.1 nM. It is applicable in research on inflammatory and autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

TNF-α-IN-8 (compound I-42) is an isoindole-imide inhibitor of tumor necrosis factor-alpha (TNF-α), used in research on cancer, heart disease, osteoporosis, and autoimmune disorders. It also acts as a click chemistry reagent, with an Azide group suitable for CuAAc or SPAAC reactions with Alkyne, DBCO, or BCN groups.

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

Human TNF alpha (46-65) peptide.

Acetylcysteine (NAC) is an N-acetyl derivative of cysteine, a ROS inhibitor and mucolytic agent. Acetylcysteine induces apoptosis, can be used to reduce mucus thickness, and has anti-influenza viral activity.

Theophylline (1,3-Dimethylxanthine) is a methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac, and central nervous system stimulant activities. It inhibits the 3', 5'-cyclic nucleotide phosphodiesterase that degrades cyclic AMP, thus potentiating the actions of agents that act through adenylyl cyclases and cyclic AMP.

R-7050 (TNF-α Antagonist III) is a tumor necrosis factor receptor (TNFR) antagonist that exhibits heightened selectivity for TNFα.

TIC10 (ONC-201) inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

5-O-Caffeoylshikimic acid shows anti-oxidative activity; it also shows anti-inflammatory activity, the underlying mechanism was associated with downregulation of nuclear factor-κB.

Taurocholic acid (N-Choloyltaurine) is a bile acid involved in fat emulsification, possessing notable biological and immunomodulatory activities. It can inhibit bile duct injury induced by hepatic artery ligation by upregulating VEGF-A expression and protect cholangiocytes from TNF-α-induced damage via a PI3K-mediated pathway, and is commonly used to induce pancreatitis models.

Resatorvid (TAK-242), a selective Toll-like receptor 4 (TLR4) inhibitor, binds directly to Cys747 to prevent TLR4-TIRAP interaction, thereby blocking downstream signaling. Resatorvid exhibits antitumor, anti-inflammatory, and neuroprotective activities.

SR-318 is a potent and highly selective inhibitor of p38 MAPK, demonstrating IC50 values of 5 nM for p38α, 32 nM for p38β, and 6.11 μM for p38α/β. It possesses both anti-cancer and anti-inflammatory activity.